aTyr Pharma to Present at March Investor Conferences

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, announced participation in four virtual investor conferences in March 2021. Dr. Sanjay S. Shukla, President and CEO, will deliver a corporate overview and engage in a panel discussion on immuno-oncology at the ROTH Conference. Key events include the H.C. Wainwright Global Life Sciences Conference (March 9-10), the ROTH Conference (March 15-17), the Oppenheimer Healthcare Conference (March 17), and the Maxim Group Conference (March 17-18). Presentations will be available for registered attendees and a replay will be accessible on the company's website.

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March.

Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, the 33^rd Annual ROTH Conference, the Oppenheimer 31^st Annual Healthcare Conference and the Maxim Group Emerging Growth Virtual Conference. Dr. Shukla will also participate in a panel on immuno-oncology targets at the ROTH Conference.

Details of the events are as follows:

Conference: H.C. Wainwright Global Life Sciences Conference
Date: March 9-10, 2021
Presentation Time: On Demand

Conference: 33^rd Annual ROTH Conference
Date: March 15-17, 2021
Presentation Time: On Demand
Panel Title: Novel Immuno-Oncology Targets That Could Improve Clinical Outcomes
Panel Date: March 15, 2021
Panel Time: 2:00 p.m. Eastern Time

Conference: Oppenheimer 31^st Annual Healthcare Conference
Date: March 17, 2021
Presentation Time: 1:10 p.m. Eastern Time

Conference: Maxim Group Emerging Growth Virtual Conference
Date: March 17-18, 2021
Presentation Time: On Demand

The presentations and panel will be available for registered attendees of each conference to view. Following the events, a replay of select presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:

Ashlee Dunston

Director, Investor Relations and Corporate Communications

adunston@atyrpharma.com

FAQ

What conferences is aTyr Pharma presenting at in March 2021?

aTyr Pharma is presenting at the H.C. Wainwright Global Life Sciences Conference, the ROTH Conference, the Oppenheimer Healthcare Conference, and the Maxim Group Emerging Growth Virtual Conference.

Who is presenting for aTyr Pharma at the investor conferences?

Dr. Sanjay S. Shukla, President and CEO of aTyr Pharma, will present at the conferences.

What is the date of the ROTH Conference where aTyr Pharma is participating?

The 33rd Annual ROTH Conference will take place from March 15-17, 2021.

Will there be a replay available for aTyr Pharma's presentations?

Yes, a replay of select presentations will be available on the Investor’s section of aTyr Pharma's website after the events.

What is the focus of Dr. Shukla's panel at the ROTH Conference?

Dr. Shukla will participate in a panel discussion on novel immuno-oncology targets at the ROTH Conference.